quote

Key Takeaways Novo Nordisk prepares to report Q1 2026 results with revenues seen at $11.13B and EPS at…

Key Takeaways Novo Nordisk leads the GLP-1 market but faces rising competition and a weaker 2026 sales and…

Photo_Jubileumsveckan på 7A I 20 år har 7A erbjudit unika arbets- och mötesplatser i centrala Stockholm – med…

Photo_Jubileumsveckan på 7A I 20 år har 7A erbjudit unika arbets- och mötesplatser i centrala Stockholm – med…

Photo_Jubileumsveckan på 7A I 20 år har 7A erbjudit unika arbets- och mötesplatser i centrala Stockholm – med…

Key Takeaways NVO’s Ozempic and Wegovy drove 67% of total 2025 sales, making their Q1 performance central to…

For Immediate Release Chicago, IL – April 16, 2026 – Zacks.com announces the list of stocks featured in…

Wednesday, April 15, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today’s…

Key Takeaways Eli Lilly’s Foundayo approval introduces a direct oral GLP-1 rival to Novo Nordisk’s Wegovy pill.LLY’s strong…

Key Takeaways NVO stock dropped 36% in 3 months due to a weak 2026 outlook and rising competition…

Key Takeaways Novo Nordisk and its partner reported phase II data for UBT251 in Chinese patients with type…

Key Takeaways Novo Nordisk leads the GLP-1 market but faces slowing demand, pricing pressure and rising competition.GPCR reports…

Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock? – May 4, 2026